From Lab to Life: Stem Cell Trials Bringing Hope to Diabetics

Stem cell research is changing diabetes treatment. Instead of just managing blood sugar, these therapies aim to restore the body's natural insulin production. Recent trials show promising results:

• Vertex Pharmaceuticals (2024): 83% of participants achieved insulin independence with stem cell–derived islet cells.
• China (2024): A woman became insulin-independent using her own reprogrammed stem cells, maintaining nondiabetic A1c levels.
• Sweden (2025): CRISPR-modified cells functioned without immunosuppressants.

These therapies are advancing quickly, with Phase 3 trials and potential FDA approval for Vertex's Zimislecel therapy expected by late 2026. Families can prepare for future treatments by banking newborn stem cells, which may support diabetes therapies and other conditions. Stem cell banking offers a one-time chance to preserve these resources at birth.

Diabetes and Stem Cells: The Basics

What is Diabetes and Why is it Hard to Treat?

Diabetes comes in two main forms, each with its own set of challenges. In Type 1 diabetes (T1D), the immune system mistakenly destroys the pancreas's insulin-producing beta cells. This leads to a complete lack of insulin, forcing individuals to rely on insulin therapy for life. Globally, around 9 million people are living with T1D, and that number is projected to nearly double, reaching 17.43 million by 2040[1].

Type 2 diabetes (T2D), on the other hand, develops when the body either doesn't produce enough insulin or becomes resistant to it. While lifestyle adjustments and medications can help manage T2D, many patients eventually need insulin therapy as the condition worsens. In the U.S. alone, about 1 in 10 people has diabetes, with the majority diagnosed with Type 2.

Current treatments focus on controlling blood sugar rather than addressing the root cause of diabetes. Insulin therapy has been a game changer in terms of survival, but it can't fully mimic the body's natural glucose regulation. Patients face risks like hypoglycemia (dangerously low blood sugar), which affects about 40% of T1D patients as hypoglycemia unawareness - a condition where warning signs of low blood sugar are absent. Long-term high blood sugar also leads to serious complications, such as kidney failure, nerve damage, and heart disease. While cadaveric islet transplantation can restore some insulin production, this option is limited by a shortage of donors and the requirement for lifelong immunosuppressants. Even then, only about 25% of recipients remain insulin-independent five years after the procedure[2].

To tackle these challenges, researchers are shifting their focus from managing symptoms to regenerating functional beta cells.

How Stem Cells Could Change Diabetes Treatment

Stem cell therapy takes a different approach by aiming to replace the insulin-producing beta cells that are lost or damaged. Scientists are using directed differentiation techniques on human embryonic stem cells (hESCs) and patient-derived induced pluripotent stem cells (iPSCs) to create glucose-responsive beta cells. iPSCs are particularly promising since they can be generated from a patient’s own cells, potentially lowering the chances of immune rejection.

In a groundbreaking case in June 2023, a research team led by Deng Hongkui at Peking University transplanted about 1.5 million chemically induced iPSC-derived islets into the abdominal muscle of a 25-year-old woman with T1D. Just 2.5 months after the procedure, she achieved complete insulin independence and maintained stable blood sugar levels for over a year.

These advancements highlight how stem cell therapy could provide longer-lasting solutions by restoring the body’s natural glucose regulation. This growing field also points to exciting possibilities, such as newborn stem cell banking, which could play a role in future diabetes treatments.

Recent Advances in Stem Cell Trials for Diabetes

Recent trials have built on earlier discoveries, fine-tuning stem cell therapies to make them more effective for diabetes treatment.

Vertex Pharmaceuticals' Zimislecel Therapy

Vertex Pharmaceuticals has made notable progress with Zimislecel (previously VX-880), a stem cell-derived therapy. This treatment involves a single infusion of lab-grown islet cells into the hepatic portal vein, where they settle in the liver and start producing insulin based on glucose levels.

In June 2025, Dr. Michael R. Rickels from the University of Pennsylvania shared findings from the FORWARD-101 Phase 1/2 trial at the American Diabetes Association's 85th Scientific Sessions. The trial involved 12 adults with Type 1 diabetes, who had been living with the condition for an average of 22 years and no longer produced insulin naturally. The results were promising: a 92% average reduction in daily insulin use, with every participant maintaining glucose levels within the target range (70–180 mg/dL) for over 70% of the time.

"It's remarkable to see 12 out of 12 patients with baseline HbA1c above 7% and multiple severe hypoglycemic events reach consensus targets for glycemic control... as well as elimination of severe hypoglycemic events." – Michael R. Rickels, MD, MS, Medical Director of the Pancreatic Islet Cell Transplant Program, University of Pennsylvania

Unlike earlier treatments that depended on cells from deceased donors, Zimislecel can be produced in large quantities, potentially helping around 60,000 people in the U.S. with severe Type 1 diabetes. Vertex plans to submit regulatory applications to the FDA and EMA by 2026, with Phase 3 trials already underway. Meanwhile, global efforts to combat diabetes with stem cell therapies continue to expand.

Chinese Stem Cell Research for Type 2 Diabetes

In China, researchers have made strides in treating diabetes using autologous stem cells, which are derived from the patient’s own body, reducing the likelihood of immune rejection.

In July 2021, Dr. Yin Hao and his team at Shanghai Changzheng Hospital treated a 59-year-old man with Type 2 diabetes. The patient, who had lived with the condition for 25 years, received a transplant of autologous endoderm stem cell-derived islet cells. Within 11 weeks, he no longer needed insulin, and after a year, he was able to stop all oral diabetes medications. This case demonstrates the potential for stem cell therapies to help not just Type 1 patients but also those with advanced Type 2 diabetes who have lost significant beta cell function.

Two-Part Cellular Therapy: A New Approach

Researchers are also exploring combination therapies to improve the safety and durability of treatments. These approaches pair stem cell transplants with immune system modulation techniques, such as CAR-T regulatory cells or mesenchymal stem cells combined with Vitamin D, to protect transplanted islet cells from autoimmune attacks while encouraging beta cell regeneration.

Another promising development comes from the University of British Columbia and ViaCyte, with their VC-02 device. This small implant contains millions of lab-grown islet cells. Its design allows glucose and insulin to pass through freely while shielding the cells from immune attacks. In a November 2023 trial, one participant saw their time in the target glucose range increase from 55% to 85%, along with a 44% reduction in daily insulin needs.

"Each device is like a miniature insulin-producing factory." – Dr. Timothy Kieffer, Professor, UBC

Additionally, CRISPR gene-editing technology offers another avenue by modifying stem cells so they can avoid detection by the immune system. This could eliminate the need for immunosuppressive drugs, enabling transplanted cells to function normally. These combined therapies represent a new direction in making stem cell treatments safer and more available for diabetes patients.

Newborn Stem Cell Banking and Diabetes Research

How Cord Blood and Tissue Support Diabetes Research

Umbilical cord blood and tissue are proving to be valuable resources in the fight against diabetes, thanks to two types of stem cells they contain. Hematopoietic stem cells (HSCs), found in cord blood, are being studied for their potential to "reset" the immune system in patients with Type 1 diabetes. This could halt the autoimmune attack on insulin-producing beta cells. Meanwhile, mesenchymal stem cells (MSCs), derived from cord tissue, are known for their anti-inflammatory and immune-regulating properties. These qualities may protect remaining insulin production and help address complications like diabetic kidney disease.

Between 2019 and 2023, the Medical University of South Carolina, in collaboration with the NIDDK, conducted a clinical trial using MSCs from donor-derived cord tissue to treat Type 1 diabetes. The trial explored how these cells could suppress harmful autoimmune responses. In Sweden, NextCell reached Phase III trials in 2023, following earlier successful trials conducted with Karolinska University Hospital. These earlier phases confirmed the therapy's safety and its potential to preserve natural insulin production.

Newborn stem cells are often regarded as more "pristine" compared to adult stem cells. They have a higher ability to multiply and offer greater flexibility when matching donors and recipients. For families, this is especially important since diabetes often has a genetic link. Preserved newborn stem cells are a 100% genetic match for the baby and may also be compatible with siblings or parents, making them a valuable resource for potential future treatments.

Americord Registry: Helping Families Preserve Stem Cells for Future Treatments

To make these advancements accessible, companies like Americord Registry provide practical solutions for preserving newborn stem cells. Through a straightforward, non-invasive collection process right after birth, families can store umbilical cord blood, cord tissue, and placental tissue in long-term cryogenic facilities. This preservation keeps the cells viable for future breakthroughs in diabetes treatment and other medical conditions.

Americord Registry offers a variety of plans tailored to family needs. Their Essential Family Plans focus on preserving cord blood using CryoMaxx™ Processing, while their Maximum Family Plans include storage for cord tissue, placental tissue, and even exosomes from both the newborn and the mother. Banking both cord blood and cord tissue ensures access to HSCs for immune system support and MSCs for tissue repair and regeneration. With research progressing rapidly at institutions like the University of Chicago and Mayo Clinic, families who choose to bank stem cells today are preparing for the possibility of participating in tomorrow's medical advancements.

Challenges and Future Directions in Stem Cell Therapy

Current Challenges in Stem Cell Research and Trials

While recent trials in stem cell therapy for diabetes have shown promise, several obstacles still stand in the way of making this treatment widely accessible. One of the biggest challenges is immunosuppression. Patients undergoing this therapy must take strong drugs to prevent their immune systems from rejecting the transplanted cells. Unfortunately, these medications come with serious risks, including infections and cancers. For example, in the Vertex FORWARD trial, 21% of participants experienced neutropenia, and one death was linked to the immunosuppressive treatment.

Another issue lies in scaling up production to meet Good Manufacturing Practice standards. Current methods struggle to consistently produce the 10,000 islet equivalents per kilogram needed for full insulin independence. Adding to the complexity are varying international regulatory standards, which make global development more difficult. Strict donor screening requirements for infectious agents further drive up costs and slow progress.

What's Next for Stem Cell Therapy in Diabetes

Despite these hurdles, researchers are making strides toward safer and more efficient therapies. One exciting development is the use of CRISPR gene editing to create "stealth" or "hypoimmune" cells that can avoid detection by the immune system. In June 2025, Dr. Jia Zhao and a team at the University of British Columbia unveiled data on genetically engineered human embryonic stem cells modified with eight protective genes to evade immune attacks. These cells also include an "inducible kill switch" that can be activated by the FDA-approved antiviral drug Ganciclovir, allowing doctors to destroy the transplanted cells if they grow uncontrollably.

"These early results show potential for safer, longer term cell therapy for diabetes as we look to provide patients with solutions without the need for harmful immune-suppressing drugs." - Jia Zhao, PhD, Postdoctoral Researcher, University of British Columbia

Vertex Pharmaceuticals is planning to submit regulatory filings for zimislecel to agencies like the FDA, European Medicines Agency, and UK Medicines and Healthcare products Regulatory Agency by 2026. Researchers are also exploring alternative transplantation sites beyond the liver's portal vein. For instance, the abdominal rectus sheath has shown promise as a location that may improve cell survival and make monitoring easier.

Additionally, advancements like 3D suspension bioreactors could help resolve supply issues by enabling large-scale production of clinical islet cells. With around 2 million Americans living with Type 1 diabetes and about 125,000 facing severe forms of the disease, these innovations could reshape treatment options over the next decade. By addressing current limitations, these breakthroughs could bring the field closer to realizing its full potential.

What Families Should Know About Stem Cell Banking

Benefits of Cord Blood and Tissue Banking

As stem cell therapies transition from research to real-world applications, families play a key role in preparing for potential future treatments through newborn stem cell banking. For families with a history of diabetes, this is often referred to as "biological insurance." By banking these cells, families secure a genetically matched resource that could support future health needs.

Cord blood is rich in hematopoietic stem cells (HSCs), which can help reset the immune system in cases like Type 1 diabetes. Meanwhile, cord tissue contains mesenchymal stem cells (MSCs), which researchers are studying for their potential to regulate immune responses and stabilize blood sugar levels. Clinical trials for stem-cell-derived islet therapies in 2025-2026 showed promising results, with some participants reducing their daily insulin needs by 90% and about 83% maintaining functional insulin production a year later.

Banking both cord blood and tissue expands access to emerging treatments. Cord blood stem cells are currently FDA-approved for over 80 medical conditions. For families concerned about diabetes, timing is critical. Autologous cord blood infusions - using the patient’s own cells - have shown the most promise when administered early, during the "honeymoon phase" of Type 1 diabetes, when the body still produces some insulin.

Modern stem cell banking also offers practical benefits. Many providers now use 5-compartment storage vials, allowing families to use portions of the stored sample for multiple treatments rather than depleting it all at once. Costs for collection and processing range from $300 to $2,300, with annual storage fees between $100 and $175. Considering that future stem-cell-derived islet therapies are expected to cost between $100,000 and $250,000 per patient in the U.S., banking stem cells could prove to be a cost-effective choice over time.

With these potential advantages, selecting a reliable stem cell banking partner becomes a critical step for families.

Choosing a Stem Cell Banking Partner

As clinical advancements continue to open doors for new treatments, ensuring high-quality stem cell banking is more important than ever. To make the most of this opportunity, choosing a trustworthy provider is essential. Start by confirming that the provider is both FDA-registered and AABB-accredited - these credentials guarantee compliance with strict standards for processing and long-term storage. It’s also recommended that families finalize their choice by the 34th week of pregnancy to allow enough time for collection kits and consent forms to be prepared. Opt for providers that bank both cord blood and cord tissue, as MSCs from cord tissue are a key focus in Type 2 diabetes research.

Americord Registry is one example of a provider offering a range of plans, from the Essential Family Plan (cord blood only) to the Maximum Family Plan, which includes cord blood, cord tissue, placental tissue, and exosome banking for both newborns and mothers. Their CryoMaxx™ Processing system is designed to preserve growth factors and cytokines by minimizing tissue manipulation, which could enhance the cells’ future therapeutic potential.

Transparency is vital when storing stem cells that might not be used for decades. Americord, for instance, offers clear pricing and a Cord Blood Quality Guarantee valued up to $110,000. They also accommodate delayed cord clamping - a practice many parents prefer - since only about 40 mL of blood is typically needed for storage, leaving plenty of volume after a 1-3 minute delay.

Be cautious of clinics that promise immediate cures. Currently, legitimate stem cell therapies for diabetes are primarily available through clinical trials listed on ClinicalTrials.gov. A reputable banking partner should have a proven track record of their samples being successfully used in clinical trials or treatments, ensuring their preservation methods are reliable when it matters most.

Conclusion

Advances in the lab are quickly turning into therapies that could change lives. Recent clinical trials have shown promising results, bringing us closer to a future where insulin independence might become a reality for people with diabetes. These developments don’t just challenge the way diabetes is traditionally managed - they open the door to treatments that tackle the disease at its core instead of just managing symptoms.

What’s exciting is that these aren’t just small steps forward. They represent a shift in focus - from managing diabetes as a lifelong condition to exploring the possibility of functional cures. Researchers have shown that stem cell therapies can help the body regain its natural ability to regulate blood sugar, offering hope for a life without the need for constant insulin injections.

Amid this progress, families now have a special chance to preserve newborn stem cells at their peak biological quality. With clinical research advancing steadily, banking these cells could be seen as a forward-thinking move for future health. For example, Phase III trials for Zimislecel are aiming for potential FDA approval by late 2026, bringing these therapies closer to being widely available.

Choosing to store cord blood and tissue is about keeping options open. While the future of these therapies is still unfolding, evidence suggests that using a patient’s own stem cells - perfectly matched to their body - could play a major role in upcoming diabetes treatments. For families with a history of diabetes or those wanting to prepare for unknown medical challenges, this is a once-in-a-lifetime opportunity tied to birth. The future of diabetes care is evolving right now, and the cells preserved today might hold the key to tomorrow’s breakthroughs.

FAQs

Who is eligible for stem cell islet therapy trials?

Individuals with type 1 diabetes might be eligible for stem cell islet therapy trials, particularly if they struggle with impaired hypoglycemic awareness or have a history of severe hypoglycemic episodes. These trials typically target those facing serious difficulties in maintaining stable blood sugar levels.

Will these treatments require lifelong immunosuppressants?

Many newer stem cell therapies for type 1 diabetes are designed to eliminate the need for lifelong immunosuppressants. This is particularly the case with treatments that use autologous stem cells (stem cells derived from the patient's own body) or specially engineered cell transplants that reduce the risk of immune rejection. That said, there are situations - like when a patient is already on immunosuppressive therapy - where continued use of these medications might still be required.

Does cord blood or cord tissue banking matter for diabetes?

Banking cord blood and tissue holds promise for addressing diabetes, particularly type 1. These sources are rich in stem cells that could play a role in regenerative therapies. Cord blood contains both hematopoietic and mesenchymal stem cells, while cord tissue is a source of mesenchymal stem cells. Researchers are exploring how these cells might help regenerate insulin-producing cells and potentially regulate autoimmune responses. This suggests that storing cord blood or tissue today could pave the way for personalized treatments in the future for those managing or at risk of diabetes.